Monkeypox Concept(BK4583),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BK4583 Monkeypox Concept

Closed 04-10 16:00:00 EDT

1,899.81

-42.81

-2.20%

High1,946.82	Low1,894.16	Vol64.96M
Open1,942.67	D1 Closing1,942.62	Amplitude2.71%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O930.39M	T/O Rate--	Tradable Shares0.00
P/B4.705594	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BK4583","market":"US","secType":"PLATE","nameCN":"Monkeypox Concept","latestPrice":1899.809,"timestamp":1775851199999,"preClose":1942.6185,"halted":0,"volume":64961843,"delay":0,"changeRate":-0.022037,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-42.80957,"latestTime":"04-10 16:00:00 EDT","open":1942.6732,"high":1946.8209,"low":1894.1646,"amount":930390584.248342,"amplitude":0.027106,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1775865600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.705594,"peRate":36.914893,"turnoverRate":0.024062,"increases":2,"decrements":8,"flats":0,"marketCap":210429065706.6875,"floatMarketCap":209597223022.5},"requestUrl":"/m/hq/s/BK4583/tweets","defaultTab":"tweets","newsList":[{"id":"2626414819","title":"Gilead Sciences Inc. Stock Underperforms Friday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2626414819","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626414819?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:35","pubTimestamp":1775853300,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  slipped 2.18% to $138.99 Friday, on what proved to be an all-around rough trading session for the stock market, with the S&P 500 Index  falling 0.11% to 6,816.89 and Dow Jones Industrial Average  falling 0.56% to 47,916.57.The stock's fall snapped a two-day winning streak.Gilead Sciences Inc. closed 11.63% below its 52-week high of $157.29, which the company reached on February 11th.The stock demonstrated a mixed performance when compared to some of its competitors Friday, as Johnson & Johnson  fell 1.18% to $238.46, Pfizer Inc.  fell 1.10% to $26.92, and Abbott Laboratories  fell 2.36% to $100.30.Data source: Dow Jones Market Data, FactSet. Data compiled April 10, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002224.SGD","LU0070217475.USD","LU1585245621.USD","LU1221951129.SGD","BK4559","LU1894683264.USD","LU1571399168.USD","LU2089984988.USD","LU0466842654.USD","SG9999015952.SGD","SGXZ23171101.USD","SG9999004303.SGD","LU1674673428.USD","LU1934455194.USD","LU0882574055.USD","SG9999013999.USD","BK4592","LU1983299246.USD","LU2129689431.USD","LU0965508806.USD","LU0889566641.SGD","LU1121112475.USD","LU1934455863.HKD","BK4534","LU1244550494.USD","LU2133065610.SGD","IE00BLSP4239.USD","LU0994945656.USD","LU1061106388.HKD","LU1221951046.USD","LU1721429402.USD","LU2237957902.USD","IE00BJT1NW94.SGD","LU0456855351.SGD","LU1043141396.HKD","LU1244550221.USD","IE000WAW04H5.SGD","LU2112291526.USD","BK4566","LU1430594728.SGD","LU2430703095.HKD","LU2471134952.CNY","IE00B42XCP33.USD","LU1989763690.USD","IE0034235303.USD","LU0985320562.USD","SG9999003800.SGD","LU0124676726.USD","LU0432979614.USD","SG9999011175.SGD","LU0689626769.HKD","LU1037948897.HKD","LU2471134523.USD","LU0823416689.USD","LU0965509101.SGD","LU0912757837.SGD","LU1267930813.SGD","LU2602419157.SGD","LU0345769631.USD","SG9999015945.SGD","BK4532","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0426412945.USD","SG9999001176.USD","LU0225284248.USD","LU0122379950.USD","LU0345769128.USD","LU0792757196.USD","LU0234572021.USD","BK4599","LU1032955483.USD","LU0965509283.SGD","IE00B3T34201.USD","IE0001KFT4U8.USD","LU2430703178.SGD","BK4504","LU0345770993.USD","GILD","LU0640476718.USD","LU1732800096.USD","LU2750360997.AUD","IE000SO60NU8.SGD","LU0683600562.USD","IE000M9KFDE8.USD","LU0321505868.SGD","LU1496350502.SGD","LU1066051811.HKD","LU1261432733.SGD","LU0098860793.USD","LU0203347892.USD","IE0000B7K699.USD","IE00B7SZLL34.SGD","LU2750360641.GBP","LU0985481810.HKD","LU0426417589.USD","LU0114720955.EUR","LU0225771236.USD","IE000MB6IJN5.SGD","IE00BVYPNW00.USD","LU1839511570.USD","IE000F7OJYX1.SGD","LU1280957306.USD","LU0345770308.USD","LU0321505439.SGD","LU1691799644.USD","IE00B3PB1722.GBP","LU1929549753.HKD","LU0266013472.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","LU1934455277.USD","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","SG9999015986.USD","LU1162221912.USD","LU1935042991.SGD","LU2237957811.SGD","LU0109394709.USD","BK4588","LU1074936037.SGD","IE00BVYPNV92.GBP","BK4581","IE0002141913.USD","BK4568","LU1883839398.USD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU1778281490.HKD","LU0868494617.USD","LU0787776722.HKD","LU1196500208.SGD","LU1066051225.USD","SGXZ57979304.SGD","LU1059921491.USD","LU1043141123.HKD","LU2129689514.USD","LU1718418525.SGD","BK4082","BK4583","LU1023059063.AUD","LU1037948541.HKD","LU0170899867.USD","IE00B19Z3B42.SGD","LU1721429741.USD","LU2087621335.USD","BK4550","LU1506573853.SGD","IE0009355771.USD","IE0002270589.USD","LU0795875086.SGD","LU2211815571.USD","SG9999015978.USD","LU2430703251.USD","IE00BBT3K403.USD","LU2471134879.HKD","LU0058720904.USD","LU1894683348.USD","LU0289739699.SGD","IE00B1BXHZ80.USD","IE00BGHQF631.EUR","BK4139","BK4533","LU1032466523.USD","LU1914381329.SGD","BK4585","SG9999001176.SGD","IE000BZT7R73.USD","LU1989763427.SGD","IE00B19Z3581.USD","LU2324357040.USD","LU0965509010.AUD","LU2505996509.AUD","BK4007","LU1244550577.SGD","IE00BFXG1179.USD","LU0306807586.USD","LU0203345920.USD","BK4578","LU0306806265.USD","SGXZ41872573.SGD","LU2129689605.HKD","LU1066053197.SGD","LU1732799900.SGD","LU1066051498.USD","LU0320765992.SGD","LU0234570918.USD","LU2471134796.USD","SG9999001440.SGD","IE00BZ1G4Q59.USD","IE00BDGV0183.EUR","LU2347655156.SGD","LU0889565916.HKD","LU1674673691.USD","LU0320765646.SGD","LU0861579265.USD","LU2468319806.SGD","LU2505996681.GBP","SG9999002232.USD","LU2592432038.USD","LU1057294990.SGD","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626488601","title":"Virax Biolabs raises $5 million in private placement via pre-funded warrants, options","url":"https://stock-news.laohu8.com/highlight/detail?id=2626488601","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626488601?lang=en_us&edition=fundamental","pubTime":"2026-04-11 04:16","pubTimestamp":1775852167,"startTime":"0","endTime":"0","summary":"Virax Biolabs raised USD 5 million in a private placement announced Dec. 3, 2025.Deal issued pre-funded warrants for 12,500,000 ordinary shares, priced at USD 0.4 per warrant.Financing also included preferred investment options for up to 12,500,000 ordinary shares with an exercise price of USD 0.4.Pre-funded warrants carried an exercise price of USD 0.0001 per share, exercisable immediately with no expiry.As of April 10, 2026, all pre-funded warrants were exercised, lifting ordinary shares outstanding to 19,923,432.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL60Tgyx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","BK4175","VRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626118646","title":"Gilead price target raised to $175 from $171 at Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2626118646","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626118646?lang=en_us&edition=fundamental","pubTime":"2026-04-10 20:57","pubTimestamp":1775825860,"startTime":"0","endTime":"0","summary":"Morgan Stanley raised the firm’s price target on Gilead (GILD) to $175 from $171 and keeps an Overweight rating on the shares. The firm adjusted mo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-175-from-171-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-175-from-171-at-morgan-stanley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0528227936.USD","BK4585","LU1430594728.SGD","LU2023251221.USD","LU1934455194.USD","BK4583","LU0882574139.USD","LU0158827781.USD","LU2112291526.USD","LU1732800096.USD","SG9999015986.USD","LU1066053197.SGD","LU1934455863.HKD","LU0114720955.EUR","LU2133065610.SGD","BK4550","LU0320765646.SGD","LU1674673428.USD","LU1839511570.USD","LU2347655156.SGD","LU0861579265.USD","IE00BSNM7G36.USD","LU1244550577.SGD","LU2028103732.USD","LU2087621335.USD","LU1720051108.HKD","LU0106261372.USD","LU2111349929.HKD","GILD","BK4516","LU1363072403.SGD","LU1674673691.USD","LU2271345857.HKD","LU1244550494.USD","LU0965509010.AUD","LU0158827948.USD","IE00B7SZLL34.SGD","BK4568","LU1585245621.USD","LU2468319806.SGD","LU0267386448.USD","IE00B19Z3B42.SGD","LU0795875086.SGD","LU0314104364.USD","LU1023059063.AUD","BK4504","LU0320765992.SGD","LU0965509283.SGD","BK4532","LU1061106388.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626191297","title":"Viatris to present Phase 3 MR-141 presbyopia trial data at ASCRS meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2626191297","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626191297?lang=en_us&edition=fundamental","pubTime":"2026-04-10 18:59","pubTimestamp":1775818786,"startTime":"0","endTime":"0","summary":"Viatris outlined four data presentations for ASCRS Annual Meeting in Washington, D.C., April 10-13, including new Phase 3 readouts for phentolamine ophthalmic solution programs.Full results from VEGA-3, Phase 3 study of MR-141 for presbyopia, will be presented, highlighting durable improvement in near vision.LYNX-2 Phase 3 data on MR-142 in post-refractive surgery patients will be presented as an encore, supporting use in low-light visual disturbance.Post-hoc analysis from MIRA-2 Phase 3 study will be shown, indicating RYZUMVI can improve image quality when reversing pharmacologically induced pupil dilation.Phase 1 study results for varenicline solution nasal spray in healthy Japanese adults will be presented, focusing on tear-related effects.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL2swvqM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4007","LU1839511570.USD","BK4583","LU2087621335.USD","VTRS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626729196","title":"E-Home Household Service files Form 3 for CFO Chunsheng Zhu initial ownership","url":"https://stock-news.laohu8.com/highlight/detail?id=2626729196","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626729196?lang=en_us&edition=fundamental","pubTime":"2026-04-10 18:08","pubTimestamp":1775815686,"startTime":"0","endTime":"0","summary":"E-Home Household Service CFO Chunsheng Zhu filed an initial beneficial ownership statement.Filing reported direct ownership of 1 ordinary share as of April 1, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. E-Home Household Service Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 10, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260410:nNDL64vPRJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","EJH","BK4583","BK4192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626539671","title":"Inovio Pharmaceuticals Inc. Stock Underperforms Thursday When Compared To Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2626539671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626539671?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:25","pubTimestamp":1775769900,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Inovio Pharmaceuticals Inc.  shed 3.67% to $1.05 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 0.83% to 22,822.42 and the Dow Jones Industrial Average  rising 0.58% to 48,185.80.Inovio Pharmaceuticals Inc. closed 64.75% short of its 52-week high of $2.98, which the company reached on September 9th.The stock underperformed when compared to some of its competitors Thursday, as Johnson & Johnson  rose 0.00% to $241.31, Statera Biopharma Inc.  rose 300.00% to $0.00, and Pfizer Inc.  fell 0.91% to $27.22.Trading volume  eclipsed its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 9, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2602419157.SGD","LU0345769128.USD","LU2129689605.HKD","LU1983299246.USD","LU0683600562.USD","LU1066053197.SGD","IE0009355771.USD","BK4533","LU0234570918.USD","LU2089984988.USD","LU2112291526.USD","LU0070217475.USD","LU0426412945.USD","LU0889566641.SGD","LU1929549753.HKD","LU0795875169.SGD","LU2430703178.SGD","SG9999002232.USD","IE00B3PB1722.GBP","LU2129689431.USD","LU1023059063.AUD","LU0170899867.USD","IE00B1BXHZ80.USD","LU1244550577.SGD","BK4559","IE000MB6IJN5.SGD","LU1196500208.SGD","IE00B7SZLL34.SGD","IE00B2B36J28.USD","LU0787776722.HKD","LU1066051811.HKD","LU0345770308.USD","LU1244550494.USD","IE00BLSP4452.SGD","LU1732799900.SGD","LU1066051498.USD","IE00BZ1G4Q59.USD","LU0985481810.HKD","LU1043141396.HKD","LU1674673428.USD","LU1883839398.USD","LU0456855351.SGD","LU1059921491.USD","IE00BSNM7G36.USD","LU1496350502.SGD","LU2471134879.HKD","IE00BFTCPJ56.SGD","LU2750360641.GBP","IE00BJJMRZ35.SGD","SG9999011175.SGD","LU2347655156.SGD","IE00B42XCP33.USD","LU1732800096.USD","IE00BJT1NW94.SGD","BK4583","BK4568","IE00BGHQF631.EUR","SG9999002224.SGD","LU0321505439.SGD","IE00B3T34201.USD","BK4504","LU0795875086.SGD","IE000SO60NU8.SGD","LU1061106388.HKD","LU2471134952.CNY","LU2505996681.GBP","BK4585","LU0345769631.USD","IE000M9KFDE8.USD","LU0882574055.USD","LU1914381329.SGD","LU2129689514.USD","IE0002270589.USD","LU0432979614.USD","LU1221951046.USD","INO","LU1430594728.SGD","LU1267930813.SGD","LU0122379950.USD","LU1778281490.HKD","LU0306806265.USD","BK4550","LU2133065610.SGD","LU0320765646.SGD","LU2471134523.USD","LU0466842654.USD","LU2430703095.HKD","LU1935042991.SGD","BK4588","LU1043141123.HKD","IE0002141913.USD","LU1718418525.SGD","LU0426417589.USD","LU0792757196.USD","SG9999001176.USD","LU0321505868.SGD","LU1506573853.SGD","BK4532","LU2505996509.AUD","BK4534","SG9999013999.USD","LU1121112475.USD","LU0225284248.USD","SGXZ57979304.SGD","IE00BFXG1179.USD","LU0203345920.USD","LU1032466523.USD","IE000WAW04H5.SGD","IE00BLSP4239.USD","LU0234572021.USD","LU1162221912.USD","LU2750360997.AUD","IE0001KFT4U8.USD","LU1894683348.USD","LU0225771236.USD","LU2592432038.USD","LU0689626769.HKD","LU0114720955.EUR","LU0306807586.USD","BK4592","LU2430703251.USD","LU1066051225.USD","LU2471134796.USD","LU0124676726.USD","LU1280957306.USD","BK4007","LU1674673691.USD","LU1032955483.USD","LU0994945656.USD","IE00BDGV0183.EUR","IE000F7OJYX1.SGD","LU0098860793.USD","LU1585245621.USD","IE00B19Z3B42.SGD","LU1894683264.USD","LU1074936037.SGD","BK4139","LU0289739699.SGD","IE00BBT3K403.USD","IE00B19Z3581.USD","SG9999001176.SGD","LU1221951129.SGD","LU0203347892.USD","LU0868494617.USD","BK4581","LU0985320562.USD","IE00B4R5TH58.HKD","IE00BVYPNW00.USD","LU0058720904.USD","LU0640476718.USD","IE00BKVL7J92.USD","BK4599","IE00BVYPNV92.GBP","LU0345770993.USD","SG9999003800.SGD","LU0912757837.SGD","LU1244550221.USD","LU2468319806.SGD","IE00BN8TJ469.HKD","IE0000B7K699.USD","IE0034235303.USD","LU1057294990.SGD","SG9999001440.SGD","IE000BZT7R73.USD","LU1261432733.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626533741","title":"DaVita Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2626533741","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626533741?lang=en_us&edition=fundamental","pubTime":"2026-04-10 05:17","pubTimestamp":1775769420,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of DaVita Inc.  rose 1.51% to $150.68 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index  rising 0.62% to 6,824.66 and the Dow Jones Industrial Average  rising 0.58% to 48,185.80.The stock's rise snapped a two-day losing streak.DaVita Inc. closed 5.48% below its 52-week high of $159.42, which the company achieved on March 2nd.The stock outperformed some of its competitors Thursday, as UnitedHealth Group Inc.  rose 0.30% to $306.91, Icon PLC  rose 0.15% to $106.70, and Quest Diagnostics Inc.  fell 0.50% to $197.82.Trading volume  remained 565,416 below its 50-day average volume of 1.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 9, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1720051017.SGD","LU0456855351.SGD","LU0661504455.SGD","SG9999014906.USD","LU0417517546.SGD","LU0949170772.SGD","LU2362541513.USD","LU0198837287.USD","LU2552382132.HKD","LU0053666078.USD","LU1670627923.USD","LU0158827781.USD","BK4567","LU0823417737.USD","LU1261432733.SGD","LU1983299246.USD","IE0002270589.USD","LU0426417589.USD","LU0728928796.USD","LU0316494557.USD","LU0795875086.SGD","LU2357305700.SGD","LU0203345920.USD","LU2360032135.SGD","LU2506952097.USD","LU0175139822.USD","SG9999014880.SGD","IE00B19Z8W00.USD","LU1035773651.USD","IE0002141913.USD","LU1732800096.USD","LU2552382058.USD","LU0823416689.USD","LU1732799900.SGD","LU0107464264.USD","BK4533","LU1074936037.SGD","LU2236285917.USD","IE00BZ1G4Q59.USD","LU0289960550.SGD","LU2461242641.AUD","LU0251132253.USD","IE00B1BXHZ80.USD","LU1291159041.SGD","LU0029864427.USD","LU2506952170.USD","LU0048584097.USD","SGXZ57979304.SGD","LU2211815571.USD","LU0266013472.USD","LU0820561818.USD","SG9999017495.SGD","LU0354030438.USD","LU0472753341.HKD","LU0965509010.AUD","LU2112291526.USD","LU0058720904.USD","LU1934455194.USD","LU2271345857.HKD","LU0310800379.SGD","LU1551013342.USD","LU2362540622.SGD","LU1267930490.SGD","LU0545039389.USD","LU0149725797.USD","LU1003077747.HKD","LU0994945656.USD","LU2361044865.SGD","LU1064131342.USD","LU0289739343.SGD","IE00B19Z9Z06.USD","LU0861579265.USD","LU0965508806.USD","LU0820562030.AUD","DVA","LU1153585028.USD","LU2023251221.USD","UNHG","IE00BFSS7M15.SGD","LU1066051811.HKD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU0128525929.USD","LU1854104046.USD","LU0128525689.USD","LU0109391861.USD","LU1778281490.HKD","SG9999018857.SGD","IE00BFTCPJ56.SGD","LU0097036916.USD","LU2506951958.HKD","LU0345770308.USD","IE00BKVL7J92.USD","LU0238689110.USD","LU2324357040.USD","LU0553294199.USD","LU1267930227.SGD","LU0528227936.USD","LU1061106388.HKD","LU1691799644.USD","LU0943347566.SGD","LU1267930573.SGD","LU1674673691.USD","LU2468319806.SGD","SG9999001176.USD","LU0289739699.SGD","SGXZ99366536.SGD","LU2133065610.SGD","BK4154","LU1057294990.SGD","LU0912757837.SGD","BK4121","LU0069063385.USD","LU2347655156.SGD","LU0094547139.USD","LU1323610961.USD","LU1119994496.HKD","BK4559","LU2089984988.USD","LU2491049909.HKD","IE00B19Z3B42.SGD","LU0708995401.HKD","LU2089283258.USD","IE0004445239.USD","IE00B1XK9C88.USD","IE00BJJMRY28.SGD","LU0203347892.USD","LU0787776722.HKD","LU1496350502.SGD","LU0820561909.HKD","LU2028103732.USD","LU0122379950.USD","LU1267930730.SGD","LU1814569148.SGD","LU0354030511.USD","IE00B894F039.SGD","IE00B19Z3581.USD","LU0052756011.USD","IE00B19Z9505.USD","LU2089284900.SGD","LU0965509283.SGD","SG9999014898.SGD","LU0211328371.USD","LU0976567544.SGD","LU1718418525.SGD","LU2265009873.SGD","BK4532","SGXZ81514606.USD","LU0057025933.USD","LU1066053197.SGD","LU1791710400.SGD","SG9999002224.SGD","LU1037948897.HKD","LU0079474960.USD","IE00BJT1NW94.SGD","LU0426412945.USD","IE00B19Z8X17.USD","LU0211326839.USD","LU0345770993.USD","LU1084165304.USD","LU1023059063.AUD","LU1066051498.USD","LU0557290698.USD","IE00B2B36J28.USD","BK4581","LU0342679015.USD","LU0738911758.USD","SGXZ31699556.SGD","LU0211327993.USD","LU1066051225.USD","SG9999013999.USD","LU1121112475.USD","SG9999018865.SGD","LU1670628061.USD","LU1983260115.SGD","IE00B4JS1V06.HKD","LU0792757196.USD","LU2491050071.SGD","LU1043141123.HKD","LU2491050154.USD","LU0187121727.USD","LU0011850046.USD","LU0158827948.USD","LU1934455863.HKD","IE00B4R5TH58.HKD","LU0689472784.USD","LU1934455277.USD","LU2506951875.HKD","LU0795875169.SGD","LU0882574055.USD","LU0353189680.USD","LU2125154935.USD","LU0950375773.USD","SG9999001176.SGD","UNHW","LU0708994859.HKD","LU2361044949.HKD","LU2361045086.USD","LU2552382215.SGD","IE00BKPKM429.USD","LU2111349929.HKD","IE0004445015.USD","LU0289961442.SGD","LU0234572021.USD","LU0320765059.SGD","LU0823417653.USD","BK4585","LU0211326755.USD","LU1267930813.SGD","LU2279689827.SGD","LU0965509101.SGD","IE00B19Z9P08.USD","IE000M9KFDE8.USD","LU1989771016.USD","LU0432979614.USD","IE00BZ9MQY76.HKD","LU1854103824.USD","LU2264538146.SGD","IE0009355771.USD","LU1551013425.SGD","LU1043141396.HKD","IE00BFXG1179.USD","LU2244417387.USD","LU2242649171.HKD","IE00B7KXQ091.USD","IE00BFSS8Q28.SGD","IE00BWXC8680.SGD","SG9999002232.USD","BK4534","LU1804176565.USD","LU0511384066.AUD","LU1914381329.SGD","BK4196","LU1791710582.SGD","LU0310800965.SGD","IE0005OL40V9.USD","IE00BN29S564.USD","LU2087625088.SGD","LU1037948541.HKD","BK4588","LU2125154778.USD","LU2362541273.HKD","LU1069347547.HKD","LU1674673428.USD","LU1988902786.USD","SGXZ51526630.SGD","LU0256863811.USD","LU0077335932.USD","LU0496365809.HKD","LU0310799852.SGD","LU0683600562.USD","BK4566","SG9999014914.USD","LU0672654240.SGD","LU1506573853.SGD","LU1548497426.USD","IE00BSNM7G36.USD","LU1720051108.HKD","LU0353189763.USD","LU0889566641.SGD","IE00B775H168.HKD","BK4583","IE00BJJMRX11.SGD","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626237130","title":"Emergent BioSolutions wins British Columbia order to supply Narcan nasal spray for THN program","url":"https://stock-news.laohu8.com/highlight/detail?id=2626237130","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626237130?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:25","pubTimestamp":1775766327,"startTime":"0","endTime":"0","summary":"Emergent BioSolutions received an initial order from British Columbia Provincial Health Services Authority to supply NARCAN Nasal Spray for British Columbia Take-Home Naloxone Program.Order follows BC government investment of CAD 18 million to expand program to include nasal naloxone.Rollout of NARCAN Nasal Spray across province begins this month.BC expansion builds on 2024 pilot program that distributed 60,000 nasal naloxone kits.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL37r2rd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014013.SGD","BK4583","LU2095319765.USD","BK4139","LU2210150020.SGD","BK4585","BK4112","LU2210149790.SGD","IE00BN0W2T93.GBP","IE00BKPKM429.USD","NDAQ","BK4588","SG9999014039.USD","IE00BGHQF748.EUR","SG9999014005.SGD","IE00B64PRP62.GBP","LU0314104364.USD","IE00BN0W2W23.USD","EBS","IE00B3QW5Z07.USD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626130284","title":"Emergent BioSolutions Partners With British Columbia to Supply Narcan® Nasal Spray for the Launch of the Expanded Bc Take Home Naloxone Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2626130284","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626130284?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:25","pubTimestamp":1775766307,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","EBS","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626133542","title":"Tempus AI announce strategic collaboration with Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2626133542","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626133542?lang=en_us&edition=fundamental","pubTime":"2026-04-09 22:18","pubTimestamp":1775744333,"startTime":"0","endTime":"0","summary":"Tempus AI (TEM) announced an expanded, multi-year collaboration with Gilead Sciences (GILD) aimed at building and advancing Gilead’s oncology pipel...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tempus-ai-announce-strategic-collaboration-with-gilead-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tempus-ai-announce-strategic-collaboration-with-gilead-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","LU0114720955.EUR","BK4139","LU1037948541.HKD","LU1585245621.USD","LU1430594728.SGD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU1778281490.HKD","LU0289739699.SGD","BK4578","BK4023","LU1934455194.USD","LU0234570918.USD","LU2112291526.USD","SG9999015945.SGD","LU1839511570.USD","LU0122379950.USD","BK4543","LU1674673428.USD","BK4550","IE00BSNM7G36.USD","BK4585","IE00B3T34201.USD","LU0109394709.USD","LU1861559042.SGD","LU2087621335.USD","BK4568","LU0320765992.SGD","BK4587","LU1861558580.USD","BK4583","SG9999015978.USD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU2468319806.SGD","LU1066053197.SGD","LU2324357040.USD","LU0965509283.SGD","GILD","LU0058720904.USD","LU0965509010.AUD","LU0882574055.USD","BK4532","LU1061106388.HKD","LU1037948897.HKD","TEMT","LU0861579265.USD","LU1934455863.HKD","BK4613","SG9999015986.USD","SG9999015952.SGD","BK4528","LU0823416689.USD","TEM","BK4551","LU2089984988.USD","LU0889565916.HKD","LU1066051498.USD","LU1571399168.USD","BK4611","LU1934455277.USD","IE0002270589.USD","BK4588","LU1674673691.USD","LU1057294990.SGD","LU0965508806.USD","LU1023059063.AUD","AIYY","BK4121","LU0965509101.SGD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626182743","title":"BUZZ-Tempus AI rises as it expands cancer research partnership with Gilead","url":"https://stock-news.laohu8.com/highlight/detail?id=2626182743","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626182743?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:49","pubTimestamp":1775738983,"startTime":"0","endTime":"0","summary":"BUZZ-Tempus AI rises as it expands cancer research partnership with Gilead** Shares of healthcare AI firm Tempus AI TEM.O rise 1.5% to $47.99 premarket** Co says it has expanded its multi-year partnership with Gilead GILD.O to support cancer drug research** Collaboration gives Gilead wider access to Tempus’ real-world patient data and AI tools, which analyze medical records from cancer patients - TEM** Gilead will use the platform to design clinical trials, choose drug targets and study treatment outcomes, co says** Says partnership aims to speed up development of cancer medicines by combining Tempus’ data insights with Gilead’s drugmaking expertise** Gilead has previously utilized TEM's data for its oncology research, including trial design, health outcomes analysis and clinical evidence** As of last close, stock down ~20% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nL4N40S11A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","LU0965509283.SGD","LU2087621335.USD","LU1674673428.USD","LU1066051498.USD","IE00BSNM7G36.USD","LU1066053197.SGD","BK4566","LU0861579265.USD","BK4585","LU0289739699.SGD","BK4568","IE00BKVL7J92.USD","LU2468319806.SGD","SG9999015978.USD","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","LU1037948897.HKD","LU0114720955.EUR","LU0965508806.USD","IE00BZ1G4Q59.USD","BK4583","LU0965509101.SGD","LU1861559042.SGD","LU1934455277.USD","LU2112291526.USD","LU0122379950.USD","LU1934455194.USD","LU1037948541.HKD","BK4578","LU0320765992.SGD","BK4139","LU0234570918.USD","LU1571399168.USD","SG9999015986.USD","LU1839511570.USD","LU2324357040.USD","BK4588","LU0058720904.USD","BK4121","LU0965509010.AUD","LU0882574055.USD","LU1861558580.USD","LU1023059063.AUD","LU1057294990.SGD","SG9999015945.SGD","LU1061106388.HKD","IE00B3T34201.USD","GILD","IE00B19Z3581.USD","BK4532","LU0823416689.USD","LU1934455863.HKD","BK4550","TEM","IE0002270589.USD","LU1674673691.USD","LU1585245621.USD","LU0109394709.USD","BK4613","LU1778281490.HKD","LU0889565916.HKD","TEMT","LU2089984988.USD","SG9999015952.SGD","LU1430594728.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626825641","title":"Tempus expands multi-year oncology RWE collaboration with Gilead Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2626825641","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626825641?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:31","pubTimestamp":1775737874,"startTime":"0","endTime":"0","summary":"Tempus AI expanded a multi-year strategic collaboration with Gilead Sciences to support Gilead oncology R&D using real-world evidence.Expanded agreement grants Gilead enterprise-wide access to Tempus Lens platform, including broader oncology datasets.Gilead will also use dedicated Tempus analytical services to support oncology pipeline development.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire  on April 09, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDLbVZ0Yw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0114720955.EUR","LU1674673428.USD","LU1674673691.USD","BK4588","LU1861558580.USD","LU0965509283.SGD","LU0289739699.SGD","IE00B19Z3581.USD","IE00BSNM7G36.USD","LU0965508806.USD","LU1585245621.USD","SG9999015945.SGD","BK4585","LU0965509101.SGD","LU1861559042.SGD","SG9999015952.SGD","LU1066051498.USD","LU0234570918.USD","BK4532","LU1934455863.HKD","BK4568","LU0823416689.USD","LU1057294990.SGD","LU0320765992.SGD","LU1037948541.HKD","LU1839511570.USD","SG9999015986.USD","LU0122379950.USD","LU0965509010.AUD","BK4613","LU1934455194.USD","GILD","LU1023059063.AUD","IE0002270589.USD","BK4566","LU2468319806.SGD","BK4578","LU0058720904.USD","BK4121","LU1430594728.SGD","LU2089984988.USD","LU1778281490.HKD","IE00B3T34201.USD","SG9999015978.USD","LU0109394709.USD","IE00BZ1G4Q59.USD","BK4611","LU2324357040.USD","LU1061106388.HKD","TEMT","BK4583","LU1934455277.USD","TEM","LU0889565916.HKD","BK4139","LU1571399168.USD","LU2087621335.USD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","LU1066053197.SGD","LU0882574055.USD","LU1037948897.HKD","LU0861579265.USD","LU2112291526.USD","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626618466","title":"Assembly Bio highlights positive Phase 1b HSV data for ABI-5366 at ESCMID 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2626618466","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626618466?lang=en_us&edition=fundamental","pubTime":"2026-04-09 20:08","pubTimestamp":1775736533,"startTime":"0","endTime":"0","summary":"Assembly Bio flagged positive Phase 1b data for HSV drug candidates ABI-5366 and ABI-1179 in recurrent genital herpes ahead of scientific presentations at ESCMID Global 2026 in Munich on April 17-21.ABI-5366 results will be presented in an oral session on April 20, including additional findings from a monthly-dosing cohort.ABI-1179 interim Phase 1b results were accepted for a late-breaker poster on April 21, supporting its positioning as a long-acting option for recurrent genital herpes.Both programs remain investigational and are licensed exclusively to Gilead, which holds responsibility for further development and commercialization.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL2yMkmk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","LU0861579265.USD","LU1066051498.USD","LU0234570918.USD","BK4532","IE00B19Z3581.USD","LU0965509283.SGD","LU1571399168.USD","BK4550","SG9999014039.USD","LU2112291526.USD","IE00BKVL7J92.USD","LU0889565916.HKD","IE00B64PRP62.GBP","LU0965509010.AUD","LU1934455863.HKD","LU2468319806.SGD","IE00BSNM7G36.USD","SG9999015978.USD","LU0122379950.USD","SG9999014005.SGD","GILD","LU1839511570.USD","LU2087621335.USD","BK4578","ASMB","IE00BZ1G4Q59.USD","LU1934455277.USD","SG9999014013.SGD","NDAQ","IE00BN0W2W23.USD","LU2210149790.SGD","LU1057294990.SGD","BK4583","LU1674673428.USD","LU2324357040.USD","BK4568","SG9999015986.USD","SG9999014021.USD","BK4139","LU1585245621.USD","IE00BN0W2V16.EUR","LU0882574055.USD","IE00BN0W2T93.GBP","LU1934455194.USD","LU2089984988.USD","LU1037948541.HKD","IE00B19Z3B42.SGD","LU0823416689.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626189777","title":"Cartography Biosciences: Advances Strategic Oncology Collaboration With Gilead's First Option Target Exercise","url":"https://stock-news.laohu8.com/highlight/detail?id=2626189777","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626189777?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:34","pubTimestamp":1775734451,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nFWN40S0CM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1778281490.HKD","LU0882574055.USD","LU0289739699.SGD","LU0320765992.SGD","LU0965509010.AUD","LU0058720904.USD","LU1934455863.HKD","BK4566","IE0002270589.USD","SG9999015978.USD","LU2112291526.USD","LU1057294990.SGD","LU0965509101.SGD","SG9999015952.SGD","LU1585245621.USD","LU0234570918.USD","LU1037948541.HKD","BK4588","LU1430594728.SGD","LU1839511570.USD","LU1066053197.SGD","LU1674673428.USD","LU0109394709.USD","IE00B19Z3B42.SGD","BK4532","LU0122379950.USD","LU1934455194.USD","IE00BKVL7J92.USD","BK4578","BK4568","BK4585","BK4583","LU0114720955.EUR","SG9999015986.USD","IE00B19Z3581.USD","GILD","LU2089984988.USD","LU1066051498.USD","IE00BSNM7G36.USD","LU0965508806.USD","LU2087621335.USD","LU0889565916.HKD","LU0823416689.USD","BK4139","IE00B3T34201.USD","IE00BZ1G4Q59.USD","LU1674673691.USD","LU2324357040.USD","IE00B7SZLL34.SGD","LU0965509283.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626181330","title":"Analysts Are Bullish on Top Healthcare Stocks: Inovio Pharmaceuticals (INO), Elevance Health (ELV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2626181330","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626181330?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:30","pubTimestamp":1775734252,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inovio Pharmaceuticals (INO), Elevance Health (ELV) ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-inovio-pharmaceuticals-ino-elevance-health-elv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-inovio-pharmaceuticals-ino-elevance-health-elv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0114720955.EUR","LABU","LU0251131958.USD","LU0070302665.USD","INO","LU2505996681.GBP","LU0980610538.SGD","LU1720051017.SGD","LU0557290698.USD","SG9999011175.SGD","XBI","LU1023059063.AUD","LU0882574055.USD","LU0061474960.USD","LU0106261372.USD","LU0742534661.SGD","BK4581","SG9999003800.SGD","LU0477156953.USD","LU0433182093.SGD","LU1720051108.HKD","LU0985489474.SGD","LU0345770308.USD","LU2362541273.HKD","LU0289739699.SGD","LU0211331839.USD","SGXZ23171101.USD","BK4137","BLSG","LU0314106906.USD","BK4588","LU1548497426.USD","LU0234570918.USD","BK4585","LU2244417387.USD","LU0251142724.SGD","LU0225283273.USD","BLSX","LU1489326972.SGD","LU2362540622.SGD","LU0130102774.USD","LU0130517989.USD","LU0648001328.SGD","LU2362541513.USD","LU0068578508.USD","LU0128526141.USD","LU1506573853.SGD","ELV","LU2430703095.HKD","LU0029874061.USD","LU0314104364.USD","LU0266013472.USD","LU1670628061.USD","LU0170899867.USD","LU2430703251.USD","LU1057294990.SGD","LU0345770993.USD","LU2108987350.USD","LU2237957811.SGD","LU0006306889.USD","LU1201861249.SGD","SG9999004303.SGD","LU0878866978.SGD","LU1670627923.USD","LU1983299246.USD","BK4583","BK4568","LU1815333072.USD","LU0640476718.USD","LU2430703178.SGD","LU0122379950.USD","LU0208291251.USD","LU0058720904.USD","LU0187121727.USD","BK4112","LU2592432038.USD","BK4139","LU0048573561.USD","LU2357305700.SGD","LU2237957902.USD","BK4154","LU2505996509.AUD","LU0320765489.SGD","LU0957791311.USD","SG9999001077.SGD","LU1280957306.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626318962","title":"BUZZ-Kymera rises as Gilead pays $45 million for experimental cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2626318962","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626318962?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:20","pubTimestamp":1775733628,"startTime":"0","endTime":"0","summary":"BUZZ-Kymera rises as Gilead pays $45 million for experimental cancer drug** Shares of biotech firm Kymera Therapeutics KYMR.O rise 3% to $89.50 premarket** Co says it will receive $45 million upfront from Gilead Sciences GILD.O to license KT-200, an experimental oral cancer drug** KT-200 targets CDK2, a protein that helps tumors grow; the drug is designed to remove the protein entirely, which could improve effectiveness and reduce side effects - KYMR** Co says the drug could help treat hardtotreat cancers such as advanced breast cancer, where treatment options are limited** Adds that Gilead gets global rights and will lead further development, aiming to start human studies in 2027** Says Kymera could receive up to $750 million in total payments plus royalties if the drug is approved** As of last close, stock up ~12% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nL4N40S0V1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0861579265.USD","LU1674673428.USD","LU1057294990.SGD","SG9999015978.USD","LU1061106388.HKD","LU0320765992.SGD","BK4568","SG9999015945.SGD","LU1430594728.SGD","BK4588","LU0234570918.USD","LU1066053197.SGD","LU1934455863.HKD","LU2089984988.USD","IE0002270589.USD","IE00BSNM7G36.USD","LU0289739699.SGD","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU1023059063.AUD","BK4139","LU0965508806.USD","LU0882574055.USD","LU1839511570.USD","LU1934455277.USD","LU1674673691.USD","LU0058720904.USD","LU1585245621.USD","LU1934455194.USD","BK4550","BK4583","LU2324357040.USD","SG9999015952.SGD","LU0109394709.USD","LU2468319806.SGD","LU1066051498.USD","LU1571399168.USD","LU2087621335.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU2112291526.USD","LU0965509010.AUD","BK4566","LU0889565916.HKD","LU1037948541.HKD","KYMR","GILD","LU0114720955.EUR","BK4578","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626186243","title":"Kymera Therapeutics Announces Gilead Sciences’ Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2626186243","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626186243?lang=en_us&edition=fundamental","pubTime":"2026-04-09 19:00","pubTimestamp":1775732400,"startTime":"0","endTime":"0","summary":"KT-200 is a first-in-class, oral CDK2 molecular glue degrader development candidate Option exercise of KT-200 triggers a $45 million milestone payment to Kymera from Gilead Sciences WATERTOWN, Mass., ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/09/3270789/0/en/Kymera-Therapeutics-Announces-Gilead-Sciences-Option-Exercise-to-License-KT-200-Oral-CDK2-Molecular-Glue-Degrader-Development-Candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1778281490.HKD","LU1571399168.USD","LU0882574055.USD","LU0289739699.SGD","BK4115","LU0965509010.AUD","LU0058720904.USD","LU1934455863.HKD","BK4566","IE0002270589.USD","SG9999015945.SGD","LU1057294990.SGD","SG9999015952.SGD","LU1585245621.USD","LU1061106388.HKD","LU0234570918.USD","BK4588","KT","KYMR","LU1430594728.SGD","LU1023059063.AUD","LU1066053197.SGD","LU0861579265.USD","LU1674673428.USD","LU0109394709.USD","IE00B19Z3B42.SGD","LU0122379950.USD","LU1934455194.USD","IE00BKVL7J92.USD","LU2468319806.SGD","BK4578","LU0541501648.USD","BK4568","BK4585","BK4583","LU0114720955.EUR","SG9999015986.USD","IE00B19Z3581.USD","GILD","LU2089984988.USD","IE00BSNM7G36.USD","BK4550","LU0965508806.USD","SG9999015978.USD","LU0889565916.HKD","LU0823416689.USD","IE00BZ1G4Q59.USD","LU1674673691.USD","LU2324357040.USD","IE00B7SZLL34.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626976472","title":"A Look At SIGA Technologies (SIGA) Valuation After Its Latest Special Dividend Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2626976472","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626976472?lang=en_us&edition=fundamental","pubTime":"2026-04-09 07:19","pubTimestamp":1775690391,"startTime":"0","endTime":"0","summary":"Special Dividend Announcement and Key Dates\nSIGA Technologies (SIGA) drew investor attention after its board declared a special cash dividend of $0.60 per share, payable on April 23, 2026, to shareholders of record as of April 7, 2026.\nSee our latest analysis for SIGA Technologies.\nThe special dividend news comes after a weak spell for the share price. The 30 day share price return shows an 18.21% decline and the 90 day return shows a 32.35% decline, while the 3 year total shareholder return...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/a-look-at-siga-technologies-siga-valuation-after-its-latest","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-siga/siga-technologies/news/a-look-at-siga-technologies-siga-valuation-after-its-latest","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DCF","BK4007","SIGA","BK4583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626920554","title":"Inovio Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2626920554","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626920554?lang=en_us&edition=fundamental","pubTime":"2026-04-09 05:23","pubTimestamp":1775683380,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Inovio Pharmaceuticals Inc.  rallied 3.81% to $1.09 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index  rising 2.80% to 22,635.00 and the Dow Jones Industrial Average  rising 2.85% to 47,909.92.Inovio Pharmaceuticals Inc. closed 63.41% below its 52-week high of $2.98, which the company reached on September 9th.The stock outperformed some of its competitors Wednesday, as Johnson & Johnson  rose 1.21% to $241.30, Statera Biopharma Inc.  remained unchanged, and Pfizer Inc.  rose 1.37% to $27.47.Trading volume  eclipsed its 50-day average volume of 1.4 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 8, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765646.SGD","SG9999001176.SGD","LU1894683264.USD","BK4599","LU0306807586.USD","IE00BJJMRZ35.SGD","IE00BVYPNV92.GBP","IE00BGHQF631.EUR","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE000WAW04H5.SGD","LU2112291526.USD","LU2471134796.USD","LU1066053197.SGD","IE00BLSP4239.USD","IE00BVYPNW00.USD","LU1066051811.HKD","LU0985320562.USD","LU0994945656.USD","LU0289739699.SGD","LU0882574055.USD","IE00BBT3K403.USD","LU0912757837.SGD","BK4534","LU2347655156.SGD","SGXZ57979304.SGD","IE00B3PB1722.GBP","BK4007","LU2471134879.HKD","LU1674673428.USD","IE00BFTCPJ56.SGD","SG9999013999.USD","SG9999011175.SGD","LU2129689514.USD","BK4588","LU1883839398.USD","IE00B2B36J28.USD","LU1066051498.USD","LU1244550494.USD","LU0426412945.USD","IE00B7SZLL34.SGD","LU1032466523.USD","IE0001KFT4U8.USD","IE0002141913.USD","IE00BZ1G4Q59.USD","LU1059921491.USD","LU1929549753.HKD","LU0203345920.USD","BK4550","BK4592","LU0787776722.HKD","IE0034235303.USD","LU0345770308.USD","LU1496350502.SGD","LU2750360997.AUD","LU0456855351.SGD","IE000BZT7R73.USD","LU1196500208.SGD","LU0058720904.USD","LU2430703251.USD","IE000F7OJYX1.SGD","IE00BDGV0183.EUR","LU0795875086.SGD","SG9999003800.SGD","BK4533","LU1894683348.USD","LU0683600562.USD","IE00B42XCP33.USD","BK4585","LU1074936037.SGD","LU0306806265.USD","LU2750360641.GBP","LU1121112475.USD","LU0225771236.USD","IE00BFXG1179.USD","INO","LU0466842654.USD","LU0426417589.USD","LU0234570918.USD","LU2592432038.USD","LU0098860793.USD","LU2129689605.HKD","IE00B4R5TH58.HKD","LU0321505868.SGD","LU0345770993.USD","IE000SO60NU8.SGD","LU1057294990.SGD","BK4568","LU1935042991.SGD","LU0689626769.HKD","LU1506573853.SGD","IE000MB6IJN5.SGD","LU2129689431.USD","LU0985481810.HKD","LU0122379950.USD","SG9999002232.USD","BK4504","LU0792757196.USD","LU1043141396.HKD","LU1914381329.SGD","LU1983299246.USD","IE000M9KFDE8.USD","BK4559","LU1023059063.AUD","LU1280957306.USD","LU0432979614.USD","LU2468319806.SGD","IE0002270589.USD","LU2505996681.GBP","LU1221951129.SGD","IE00BN8TJ469.HKD","LU1430594728.SGD","IE00BJT1NW94.SGD","LU2089984988.USD","BK4581","LU0889566641.SGD","LU0203347892.USD","SG9999002224.SGD","LU2505996509.AUD","LU2430703095.HKD","LU1674673691.USD","IE00BKVL7J92.USD","LU1032955483.USD","LU1244550577.SGD","BK4532","LU0114720955.EUR","LU0795875169.SGD","LU2133065610.SGD","LU0321505439.SGD","IE00B3T34201.USD","LU0345769631.USD","LU1043141123.HKD","LU1732799900.SGD","SG9999001440.SGD","LU0225284248.USD","LU0170899867.USD","LU1778281490.HKD","LU1061106388.HKD","LU2471134952.CNY","LU0640476718.USD","LU0345769128.USD","LU0070217475.USD","LU1066051225.USD","LU2602419157.SGD","LU2471134523.USD","SG9999001176.USD","IE0000B7K699.USD","BK4139","LU2430703178.SGD","BK4583","LU1221951046.USD","LU1718418525.SGD","LU1732800096.USD","IE00B1BXHZ80.USD","LU0234572021.USD","LU1162221912.USD","LU0124676726.USD","LU0868494617.USD","IE00BSNM7G36.USD","LU1267930813.SGD","IE00BLSP4452.SGD","LU1244550221.USD","LU1261432733.SGD","IE0009355771.USD","LU1585245621.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626922059","title":"Gilead Sciences Inc. Stock Rises Wednesday, Still Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2626922059","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626922059?lang=en_us&edition=fundamental","pubTime":"2026-04-09 04:34","pubTimestamp":1775680440,"startTime":"0","endTime":"0","summary":"This article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Gilead Sciences Inc.  rallied 1.97% to $141.54 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index  rising 2.51% to 6,782.81 and the Dow Jones Industrial Average  rising 2.85% to 47,909.92.Gilead Sciences Inc. closed 10.01% below its 52-week high of $157.29, which the company achieved on February 11th.The stock outperformed some of its competitors Wednesday, as Johnson & Johnson  rose 1.21% to $241.30, Pfizer Inc.  rose 1.37% to $27.47, and Abbott Laboratories  rose 1.70% to $103.56.Trading volume  remained 2.2 million below its 50-day average volume of 7.1 M.Data source: Dow Jones Market Data, FactSet. Data compiled April 8, 2026.This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","IE00BLSP4239.USD","LU2347655156.SGD","LU1037948897.HKD","LU0203345920.USD","LU2471134796.USD","IE00BFXG1179.USD","LU1718418525.SGD","SG9999001176.SGD","LU1221951129.SGD","LU1066051811.HKD","LU0234572021.USD","IE00B4R5TH58.HKD","LU2505996681.GBP","IE00BZ1G4Q59.USD","BK4082","LU2430703251.USD","LU0965509283.SGD","BK4588","LU2750360997.AUD","LU1074936037.SGD","SG9999001176.USD","LU0114720955.EUR","IE00BSNM7G36.USD","LU1221951046.USD","LU1066051225.USD","LU2471134952.CNY","LU0058720904.USD","LU0306807586.USD","IE00B3PB1722.GBP","LU0321505868.SGD","BK4007","IE00BVYPNV92.GBP","IE0009355771.USD","LU2430703178.SGD","LU1934455277.USD","LU1059921491.USD","IE00B7SZLL34.SGD","LU0320765646.SGD","LU0889565916.HKD","BK4592","LU1935042991.SGD","LU0456855351.SGD","LU0787776722.HKD","IE00B19Z3B42.SGD","LU2211815571.USD","LU1894683348.USD","LU2324357040.USD","LU2129689605.HKD","LU0225771236.USD","LU0234570918.USD","IE00BFTCPJ56.SGD","LU1721429741.USD","LU1057294990.SGD","IE00BGHQF631.EUR","LU1691799644.USD","LU1506573853.SGD","LU2089984988.USD","IE000SO60NU8.SGD","LU2087621335.USD","LU0868494617.USD","LU0225284248.USD","LU0320765992.SGD","SG9999015978.USD","IE00BJT1NW94.SGD","LU1721429402.USD","BK4566","LU2602419157.SGD","SG9999015986.USD","IE0002141913.USD","IE00BBT3K403.USD","LU1196500208.SGD","LU0170899867.USD","IE0034235303.USD","LU2133065610.SGD","LU0266013472.USD","IE00B19Z3581.USD","LU0466842654.USD","LU0889566641.SGD","BK4534","LU1267930813.SGD","LU1732799900.SGD","LU1934455194.USD","IE00BDGV0183.EUR","LU2592432038.USD","LU1061106388.HKD","BK4559","BK4533","LU0965508806.USD","LU0345769128.USD","LU0823416689.USD","LU1674673428.USD","LU2430703095.HKD","LU0985320562.USD","GILD","LU0965509010.AUD","LU1261432733.SGD","LU0912757837.SGD","LU1121112475.USD","BK4581","SG9999001440.SGD","IE00B2B36J28.USD","LU1732800096.USD","BK4532","IE00B1BXHZ80.USD","LU0306806265.USD","LU0640476718.USD","SG9999003800.SGD","SGXZ41872573.SGD","IE00B42XCP33.USD","LU1571399168.USD","LU1839511570.USD","LU1989763427.SGD","LU0098860793.USD","LU0795875086.SGD","LU1674673691.USD","IE000M9KFDE8.USD","LU1914381329.SGD","BK4550","LU0124676726.USD","LU0426412945.USD","SG9999013999.USD","LU1585245621.USD","LU2505996509.AUD","LU0795875169.SGD","BK4599","IE00BVYPNW00.USD","LU1929549753.HKD","LU0965509101.SGD","IE00BLSP4452.SGD","BK4583","LU0882574055.USD","IE00BJJMRZ35.SGD","LU1023059063.AUD","LU1032466523.USD","LU0203347892.USD","LU1037948541.HKD","LU1778281490.HKD","LU1883839398.USD","IE00BKVL7J92.USD","SG9999011175.SGD","LU0289739699.SGD","LU1032955483.USD","BK4568","IE0001KFT4U8.USD","BK4504","LU1066053197.SGD","LU1280957306.USD","LU1430594728.SGD","IE000BZT7R73.USD","LU1989763690.USD","LU0689626769.HKD","LU0345769631.USD","LU2750360641.GBP","SG9999015945.SGD","LU2471134879.HKD","LU0432979614.USD","LU0994945656.USD","SG9999002224.SGD","LU1244550577.SGD","IE000WAW04H5.SGD","LU2237957902.USD","LU0109394709.USD","SGXZ57979304.SGD","IE00B3T34201.USD","LU0792757196.USD","LU2468319806.SGD","LU0345770308.USD","LU0683600562.USD","SG9999015952.SGD","LU0861579265.USD","IE0000B7K699.USD","SGXZ23171101.USD","IE000MB6IJN5.SGD","LU1894683264.USD","IE0002270589.USD","LU1244550221.USD","LU1496350502.SGD","LU0985481810.HKD","LU2129689514.USD","LU2129689431.USD","LU1983299246.USD","LU1043141123.HKD","LU2471134523.USD","LU0122379950.USD","SG9999002232.USD","LU1934455863.HKD","LU1066051498.USD","LU0426417589.USD","IE000F7OJYX1.SGD","LU2112291526.USD","LU1162221912.USD","LU1244550494.USD","IE00BN8TJ469.HKD","LU0070217475.USD","LU0345770993.USD","LU2237957811.SGD","SG9999004303.SGD","LU0321505439.SGD","LU1043141396.HKD","BK4578"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0367},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0204},{"period":"6month","weight":0.0412},{"period":"1year","weight":0.2393},{"period":"ytd","weight":-0.0029}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"name":"BK4583","nameEN":"BK4583"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monkeypox Concept(BK4583),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monkeypox Concept(BK4583) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monkeypox Concept,BK4583,Monkeypox Concept股票,Monkeypox Concept股票老虎,Monkeypox Concept股票老虎国际,Monkeypox Concept行情,Monkeypox Concept股票行情,Monkeypox Concept股价,Monkeypox Concept股市,Monkeypox Concept股票价格,Monkeypox Concept股票交易,Monkeypox Concept股票购买,Monkeypox Concept股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monkeypox Concept(BK4583),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monkeypox Concept(BK4583) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction